Skip to main navigation
Skip to content
Aerpio Pharmaceuticals
  • Home
  • About Us
    • The Company
    • Leadership
    • Clinical Advisors
    • Board
    • Careers
  • Our Science
    • The mTOR Pathway
    • The Product
    • Publications and Abstracts
  • Pipeline
    • Pipeline Clinical Studies
    • Advanced PEComa
    • TSC1 and TSC2 Inactivating Alterations
  • Expanded Access
  • Contact
Aerpio Pharmaceuticals

Breadcrumb

  • Home >>
  • Investors >>
  • News releases >>
  • Aerpio announces initiation patient dosing time 2b study phase >>

Press Release

View printer-friendly version
<< Back
Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
Phase 2b Study Aerpio Press Release_Final.pdf 379 KB

Shareholder Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Investor Relations

  • Investor Overview
  • Stock Information
    • Stock Quote & Chart
  • Press Releases
  • Events & Presentations
    • Upcoming Events
    • Archived Events
    • Presentations
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
  • Investor Resources
    • Investor FAQ
    • Information Request
    • E-mail Alerts
    • IR Contacts
  • Home
  • Leadership
  • Pipeline
  • Contact
  • Careers